Discontinued — last reported Q4 '20
Vertex Pharmaceuticals Finance Lease ROU Asset Amortization remained flat by 0.0% to $1.80M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 76.7%, from $7.73M to $1.80M. Over 2 years (FY 2023 to FY 2025), Finance Lease ROU Asset Amortization shows a downward trend with a -58.9% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Higher amortization reflects a larger base of finance-leased assets, impacting net income without immediate cash outflows.
The periodic expense recognized to allocate the cost of a right-of-use asset under a finance lease over its useful life....
Standard metric for companies with significant capital-intensive lease obligations.
is_msft_finance_lease_right_of_use_asset_amortization| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $42.70M | $30.90M | $7.20M |
| YoY Change | — | -27.6% | -76.7% |
We use cookies for analytics. See our Privacy and Cookie Policy.